Showing 2891-2900 of 3315 results for "".
- Adaptilens Announces $1.6 Million in Seed Funding for Development of Accommodating IOLhttps://modernod.com/news/adaptilens-announces-1-6-million-in-seed-funding-for-development-of-accommodating-iol/2478536/Adaptilens announced a $1.6 million seed funding to fund the company’s development of an innovative accommodating IOL with the aim of allowing patients to live their lives free of glasses and contact lenses. The funding was led by Pillar VC with additional participat
- Zhaoke Ophthalmology Announces First Patient Completes 3-Year Enrollment in Phase 3 Myopia Trialhttps://modernod.com/news/zhaoke-ophthalmology-announced-first-patient-completes-3-year-enrollment-in-phase-3-myopia-trial/2478533/Zhaoke Ophthalmology Pharmaceutical has announced that the first patient has completed 3-year enrollment in the phase 3 CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar. The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- Health Care Experts Named to Biden’s COVID-19 Advisory Boardhttps://modernod.com/news/health-care-experts-named-to-bidens-covid-19-advisory-board/2478511/Former U.S. Surgeon General Vivek Murthy, MD, and former FDA Commissioner David Kessler, MD, will be among the public health leaders guiding the transition team for President-elect Joe Biden regarding COVID-19, according to a FierceHealthcare
- AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Diseasehttps://modernod.com/news/aao-data-experimental-rna-based-drug-addresses-the-underlying-cause-of-rare-eye-disease/2478509/At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss. P
- Clots, Strokes And Rashes. Is COVID-19 A Disease Of The Blood Vessels?https://modernod.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/Whether it’s strange rashes on the toes or blood clots in the brain, the widespread ravages of COVID-19 have increasingly led researchers to focus on how the novel coronavirus sabotages the body’s blood vessels, according to an NPR
- What a Republican Senate Will Mean for the Health Care Industryhttps://modernod.com/news/what-a-republican-senate-will-mean-for-the-health-care-industry/2478493/Republicans appear likely to hold on slightly to their Senate majority after Tuesday’s elections, which could have a major impact on what healthcare legislation gets through Congress next year, according to a FierceHealthcare
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for
- PolyActiva Appoints Tracy Valorie to its Board of Directorshttps://modernod.com/news/polyactiva-appoints-tracy-valorie-to-its-board-of-directors/2478481/PolyActiva announced the appointment of experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms. Valorie is recognized in the industry for her success in building and leading high performing teams a